Single-use bioreactors are gaining popularity as they minimize the risks of cross-contamination and product mix-ups. They offer benefits such as lower capital costs, reduced validation requirements, improved production flexibility, ease of scale-up, and disposability. Single-use bioreactors help produce biologics such as monoclonal antibodies, vaccines, and recombinant proteins more efficiently. The global Single-Use Bioreactor Market is estimated to be valued at US$ 1337.67 Mn in 2023 and is expected to exhibit a CAGR of 15% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
The increasing adoption of single-use bioreactors across different industries such as biopharmaceuticals, food & beverage and others is the major factor accelerating the growth of this market. With single-use bioreactors, manufacturing process can be scaled up or down quickly and with minimum validation requirements. This leads to less time to market and lower costs of goods. Further, single-use bioreactors reduce the risk of product cross-contamination which is a great advantage for highly sensitive products such as vaccines and monoclonal antibodies. Their disposable nature also eliminates the need for cleaning and sterilization between batches, thereby improving production flexibility for manufacturers. Owing to these advantages, the demand and sales of single-use bioreactors are expected to grow substantially over the forecast period.
Segment Analysis
The global Single-Use Bioreactor Market Demand is dominated by systems with 5L to 50L capacity. These systems account for over 50% share of the overall market owing to their flexibility and ability to meet production needs of mid-sized to large biopharmaceutical players. They are suited for both clinical and commercial production across therapeutic areas like vaccines, monoclonal antibodies, and recombinant proteins.

Key Takeaways
Regional analysis: North America remains the dominant region in the single-use bioreactor market owing to high adoption of advanced bioprocessing technologies amongst biopharma companies in the US. The region accounted for over 40% market share in 2023. Asia Pacific is expected witness highest CAGR over the forecast period driven by increasing investments in biologics production by big pharma players and establishment of new drug manufacturing facilities in China, India, and Japan.

Key players operating in the single-use bioreactor market are Sartorius AG, OmniBRx Biotechnologies, Merck KgaA, Solaris Biotechnology Srl, Eppendorf AG, Distek Inc., Celltainer Biotech BV, ABEC Inc., Thermo Fisher Scientific, and Danaher Corporation (Pall Corporation), among others. Sartorius AG dominates the market with over 20% share owing to itscomprehensive portofolio of single-use bioreactor systems and solutions across different capacity ranges.

The global single-use bioreactor market is expected to witness high growth. Advantages like lower capital cost, flexibility of production, and ease of scale-up using single-use technologies is driving adoption amongst small to mid-sized biopharma companies. In addition, need for continuous bioprocessing workflows to improve production economics is further expected to propel demand.

Get more insights on this topic:
Comments (0)
No login
Login or register to post your comment